Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of your Favored Travel Movement - 2Must-Have Cooking Machine in Your Kitchen
- 310 times the sky amazed us in 2025
- 4NASA releases stunning new images captured by the Artemis II moon mission, including 'Earthset' and a solar eclipse from space
- 5EU chief urges Iran to free imprisoned protesters, lift internet ban
- Iran war upends aviation strategies
- Merz says army could be involved in mine-clearing from Hormuz
- Amazon sued over 'punitive' handling of employee absences
- 3 astronauts settle into their new life in orbit | On the International Space Station this week Dec. 1-5, 2025
- Discovering a true sense of harmony: Contemplation and Care Practices
- The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
- NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
